NASDAQ:BCYC Bicycle Therapeutics Q3 2026 Earnings Results & Report $3.05 -0.06 (-1.93%) Closing price 04:00 PM EasternExtended Trading$3.07 +0.02 (+0.66%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Bicycle Therapeutics beat analyst expectations on both earnings and revenue in its Q3 2026 results, released October 29, 2026. The company reported EPS of -$0.15 versus the -$0.3990 consensus estimate, while revenue of $34.06 million topped the $12.22 million estimate by $21.84 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateOctober 29, 2026TimeBefore Market OpensConference Call7:00 AM ET Bicycle Therapeutics EPS ResultsActual EPS-$0.15Consensus EPS -$0.3990Beat/MissBeat by +$0.2490One Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersBicycle Therapeutics Revenue ResultsActual Revenue$34.06 millionExpected Revenue$12.22 millionBeat/MissBeat by +$21.84 millionYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Bicycle Therapeutics Q3 2026 Earnings FAQ Did Bicycle Therapeutics beat earnings estimates for Q3 2026? Bicycle Therapeutics (NASDAQ:BCYC) reported earnings of -$0.15 per share for Q3 2026, beating the consensus estimate of -$0.3990. The report was announced on Thursday, October 29, 2026. What was Bicycle Therapeutics' revenue for Q3 2026? Bicycle Therapeutics reported revenue of $34.06 million for Q3 2026, against a consensus estimate of $12.22 million. Bicycle Therapeutics Earnings HeadlinesBicycle Therapeutics (NASDAQ:BCYC) Cut to Sell at Wall Street ZenNovember 17 at 1:34 AM | americanbankingnews.comBicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Stock Has Average Price Target of $13.57 According to BrokeragesNovember 16 at 3:01 AM | americanbankingnews.comYou missed yesterday's deadline…In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.November 19 at 1:00 AM | Behind the Markets (Ad)Bicycle Therapeutics Advances Cancer Programs While Keeping Details Close, Oppenheimer SaysOctober 31, 2026 | finance.yahoo.comBicycle Therapeutics Reports Q3 Results; Nuzefatide Updates Expected In 2027October 29, 2026 | rttnews.comBicycle Therapeutics Reports Recent Business Progress and Third Quarter 2026 Financial ResultsOctober 29, 2026 | finance.yahoo.comSee More Bicycle Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Bicycle Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bicycle Therapeutics and other key companies, straight to your email. Email Address About Bicycle TherapeuticsBicycle Therapeutics (NASDAQ:BCYC) is a clinical-stage biopharmaceutical company developing medicines for serious diseases, with a focus on cancer. Founded in 2009, the company grew out of research at the University of Cambridge in the United Kingdom and has operations in Cambridge, UK, and Cambridge, Massachusetts. The company’s proprietary Bicycle platform creates small, constrained peptides that can bind to specific biological targets. Bicycle Therapeutics is using this technology to develop treatments that may be designed to reach targets that are difficult for conventional drugs to access. Its research includes Bicycle toxin conjugates, which pair target-binding peptides with therapeutic payloads, as well as radiopharmaceutical and immune-modulating approaches. The company’s products are investigational and are being developed through clinical and preclinical research.View Bicycle Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting GameWalmart Earnings Change the Narrative as Digital Growth Lifts OutlookWhatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play ItLowe's Earnings Beat Looked Strong Until a 34-Cent Tariff Refund Changed the MathApple's Next Margin Defense Could Be Hiding in Your WalletThe Uranium Price Paradox: 5 Investments Facing Very Different Tests in 2027Target Stock Is Up Over 70%—Has the Easy Money Already Been Made? Upcoming Earnings Hewlett Packard Enterprise (11/23/2026)Medtronic (11/24/2026)Analog Devices (11/24/2026)Autodesk (11/24/2026)Dell Technologies (11/24/2026)Deere & Company (11/25/2026)CrowdStrike (12/1/2026)Marvell Technology (12/1/2026)Bank Of Montreal (12/2/2026)Bank of Nova Scotia (12/2/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.